Bacterial endotoxin test: gel clot vs kinetic methods

Endotoxins are lipopolysaccharides from the outer membrane of Gram-negative bacteria. In the body they trigger fever and, at high doses, shock. They are heat-stable and survive normal steam sterilisation, so a product can be perfectly sterile and still dangerous. The bacterial endotoxin test (BET) uses Limulus amebocyte lysate (LAL), an extract of horseshoe crab blood cells, or a recombinant reagent, to detect them.

This article explains the methods, how to choose between them, how to calculate limits and dilutions, and what you must prove before a BET result can be trusted.

Where endotoxins come from

Any Gram-negative bacteria in water, raw materials, equipment or the environment can leave endotoxin behind, even after the bacteria are killed. Common sources in pharma are:

• Water systems with biofilm, especially purified water used for cleaning or as raw material
• Raw materials of natural origin, such as sugars, amino acids and some excipients
• Glass and stopper components that are not properly depyrogenated
• Process equipment that is cleaned but not dried properly, allowing growth

Controlling these sources is far more effective than relying on the final test.

The methods

Method	How it reads	Result
Gel clot (limit test)	A firm gel that survives inverting the tube 180°	Pass / fail at a set sensitivity (λ)
Gel clot (semi-quantitative)	Endpoint in a dilution series	Approximate concentration
Kinetic turbidimetric	Time for turbidity to reach a threshold	Quantitative, from a standard curve
Kinetic chromogenic	Time for colour to develop	Quantitative, from a standard curve
Endpoint chromogenic	Colour after a fixed time	Quantitative

All are run at 37 ± 1 °C, and the sample pH is normally adjusted into the range the reagent requires (often 6.0–8.0). Gel clot tubes are incubated undisturbed for 60 ± 2 minutes.

How to choose

• Gel clot is simple, cheap and robust, and it is the referee method if results disagree. It gives less information: a pass or fail at one sensitivity.
• Kinetic methods give a number, which helps trending and investigations, and they automate well with a plate reader. They need more equipment, software validation and audit trails.

Many sites use gel clot for routine release of simple products and kinetic chromogenic methods for water, raw materials and products where trending matters.

Calculating the limit and the MVD

The endotoxin limit is K/M:

• K is the threshold pyrogenic dose: 5 EU/kg for most parenterals, 0.2 EU/kg for intrathecal products.
• M is the maximum dose per kg of body weight given in one hour. Use 70 kg as the standard adult weight unless the product is for children.

The maximum valid dilution (MVD) is the largest dilution at which the limit can still be detected:

MVD = (endotoxin limit × concentration of the test solution) ÷ λ

where λ is the labelled sensitivity of the lysate (gel clot) or the lowest point of the standard curve (kinetic).

Try the endotoxin limit and MVD calculator for your own products.

Confirming the lysate (gel clot)

Before using a new lot of lysate, confirm its labelled sensitivity:

1. Prepare a series of endotoxin standards at 2λ, λ, 0.5λ and 0.25λ in LAL reagent water.
2. Test each in quadruplicate, with negative controls.
3. Find the endpoint (the lowest concentration that clots) in each replicate.
4. Calculate the geometric mean of the endpoints.

The result must be between 0.5λ and 2λ. Repeat whenever a new lysate lot is used or test conditions change.

The standard curve (kinetic methods)

For kinetic methods, run a standard curve with at least three endotoxin concentrations spanning the range you will test, in replicate. The absolute value of the correlation coefficient must be at least 0.980. Many labs run the curve with every assay; others store it, if the software and reagent manufacturer allow, and confirm it with controls.

Inhibition and enhancement

Before routine use, show that the product does not interfere with the reaction. Many products contain substances that inhibit the enzyme cascade (chelating agents, extremes of pH, some proteins) or that enhance it (glucans, some surfactants).

• Gel clot: test the product, diluted as intended, spiked with a series of endotoxin concentrations around λ. The geometric mean endpoint must be between 0.5λ and 2λ.
• Photometric methods: spike the product with a known amount of endotoxin, usually at or near the middle of the standard curve, and show recovery of the added endotoxin between 50% and 200%.

If the product interferes, dilute it (staying within the MVD), adjust pH, add a suitable buffer or use a glucan-blocking reagent, then repeat. Document the final validated conditions and test three batches before routine use.

Repeat interference testing whenever the formulation, manufacturing process or reagent supplier changes.

Routine test controls

Every routine test includes:

• Negative control: LAL reagent water, which must show no reaction.
• Positive control: endotoxin standard at 2λ (gel clot) or a curve point (kinetic).
• Positive product control (PPC): the product spiked with endotoxin, which must recover within 50–200% for kinetic methods or clot for gel clot.

An invalid control means the test is invalid and must be repeated. It does not mean the product passes.

Depyrogenation

Glassware and components that contact the product must be free of endotoxin. Dry heat is the common method, for example 250 °C for at least 30 minutes, in a depyrogenation oven or tunnel. Validate depyrogenation by showing at least a 3-log reduction of endotoxin, using indicators spiked with a known amount of endotoxin placed in the coldest parts of the load.

Recombinant reagents

Recombinant Factor C (rFC) and recombinant cascade reagents avoid using horseshoe crab blood. Ph. Eur. 2.6.32 describes rFC, and USP has published a chapter for recombinant reagents. Switching from LAL still needs a comparability study for each product, covering accuracy, precision, interference and robustness.

Common audit findings

• No inhibition and enhancement data after a formulation change
• Kinetic reader software without enabled audit trails
• Positive product controls outside 50–200% accepted without investigation
• MVD calculations using the wrong dose or body weight
• Lysate sensitivity not confirmed for a new lot
• Glassware depyrogenation not validated, or validation indicators placed in easy positions

A BET result is only as good as the controls around it. Get the calculations right, prove the product does not interfere, and keep the sources of endotoxin under control upstream.